Modalis Therapeutics Corporation has agreed to join the Ginkgo Technology Network, enabling Ginkgo’s global customers in the cell and gene therapy fields to access Modalis’ proprietary epigenome modulation technology, CRISPR-GNDM (Guide Nucleotide-Directed Modulation).   Modalis’ CRISPR-GNDM Technology is capable of activating or suppressing any gene in a controlled manner without requiring DNA cleavage. This collaboration also creates a significant opportunity for Modalis to establish additio...